On May 29, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with bevacizumab (Tecentriq and Avastin, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Read full FDA announcement.
Tecentriq prescribing information and billing/coding for HCC.
Avastin prescribing information and billing/coding for HCC.
Posted 6/2/2020
